Eli Lilly and Company

🇺🇸New York Stock Exchange
Back to all articles
Eli Lilly and Company stock analysis LLY overview
Bullish +75

Eli Lilly stock soars after Q1 earnings as revenue grows 56% on strength of GLP-1 drug sales

📈 Eli Lilly (LLY) stock surged nearly 10% on Thursday following the release of its Q1 earnings report.

💊 Revenue from GLP-1 drugs Zepbound and Mounjaro drove overall company revenue up 56% year over year to $19.7 billion.

🔼 Zepbound revenue jumped 80% to $4.16 billion, while Mounjaro sales soared 125% to $8.66 billion.

💰 Despite price reductions in the US market, strong demand resulted in GLP-1s accounting for roughly two-thirds of total sales.

✔️ A major positive catalyst was the FDA approval of Foundayo, a new oral pill version of the weight-loss drug.

🕐 The new Foundayo pill can be taken any time of day without food or water restrictions, according to CEO David Ricks.

⚠️ Despite the recent rally, LLY shares remain down approximately 13% year-to-date due to competition and pricing pressures.

🩺 Zepbound is approved for weight management, while Mounjaro is used for diabetes treatment.

Bullish Signals
  • Eli Lilly (LLY) stock soared nearly 10% on Thursday following strong quarterly earnings.
  • Revenue grew 56% year over year to $19.7 billion, driven by robust demand for GLP-1 drugs Zepbound and Mounjaro.
  • Zepbound revenue increased 80% year over year to $4.16 billion despite lower US prices.
  • Mounjaro revenue soared 125% year over year to $8.66 billion as demand continues to lift overall sales.
  • GLP-1 drugs now account for roughly two-thirds of Eli Lilly's total sales, indicating a dominant market position.
  • The FDA approved Foundayo, the only approved GLP-1 pill that can be taken any time of day without food or water restrictions.
  • Foundayo approval provides a significant tailwind to the company's weight-loss business and product pipeline.
Risk Factors
  • Despite record-breaking revenue growth, Eli Lilly's stock is down roughly 13% year-to-date due to intensifying competition and pricing pressure.
  • The strong financial performance relies heavily on GLP-1 drugs which now account for approximately two-thirds of the company's total sales, creating significant concentration risk.
  • Lower prices for Zepbound and Mounjaro in the US market were required to achieve revenue growth, indicating potential margin compression from pricing headwinds.
  • Zepbound revenues increased 80% year over year to $4.16 billion while Mounjaro soared 125% to $8.66 billion, highlighting vulnerability to any future slowdown in this dominant segment.
Full Analysis
Eli Lilly (LLY) stock surged nearly 10% on Thursday following the release of strong Q1 earnings, driven primarily by exceptional sales of its GLP-1 drugs, Zepbound and Mounjaro. These medications are used for weight management and diabetes, with Zepbound revenue climbing 80% year over year to $4.16 billion, while Mounjaro revenue jumped 125% to reach $8.66 billion. Despite facing lower prices for these drugs in the United States, robust demand allowed overall company revenue to grow by 56% year over year to $19.7 billion, with GLP-1 drugs now accounting for approximately two-thirds of Eli Lilly's total sales. The company highlighted a significant milestone achieved during the quarter: the FDA's approval of Foundayo, an oral pill version of its weight-loss drug. This development is considered a major tailwind as it offers convenience for patients who can take the medication at any time of day without restrictions on food or water intake. David Ricks, CEO of Eli Lilly, referred to this FDA approval as a "key milestone" in the company's growth trajectory. Despite the significant single-day gain, Eli Lilly shares remain down roughly 13% year to date, reflecting ongoing challenges in the sector. The stock has been weighed down by increasing competition within the weight-loss drug market and persistent pricing pressure on existing products. The strong quarterly performance underscores the continued market dominance of GLP-1 medications, yet investors are watching closely to see if the company can maintain growth momentum amid these external headwinds.